EGFR and colorectal carcinoma: MAPK is a key pathway for targeted therapy, as many CRC patients profit from anti‐EGFR or anti‐EGFR/anti‐BRAF therapy (Amado et al, 2008; Karapetis et al, 2008; Kopetz et al, 2019).